Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES HENDRICKS LEWIS

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1396745212
CMS profile
63334
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$215,442.85

152 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES HENDRICKS LEWIS

NPI 1396745212 · CMS profile ID 63334

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396745212?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES HENDRICKS LEWIS, NPI 1396745212, CMS profile ID 63334. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396745212?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAMES HENDRICKS LEWIS, NPI 1396745212, CMS profile ID 63334. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396745212?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAMES HENDRICKS LEWIS, NPI 1396745212, CMS profile ID 63334, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1396745212?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

152 matching records · $215,442.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 152 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 152.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $26.5004/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552533 CMS
Gilead Sciences, Inc. $111.6004/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552531 CMS
HRA Pharma $2,400.0003/31/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708284415 CMS
AbbVie, Inc. $24.3603/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648128567 CMS
Gilead Sciences, Inc. $11.6003/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679348205 CMS
Gilead Sciences, Inc. $3,560.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679312789 CMS
Gilead Sciences, Inc. $106.9603/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552529 CMS
Gilead Sciences, Inc. $25.0003/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552527 CMS
Gilead Sciences, Inc. $13.9203/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679348203 CMS
Sumitomo Dainippon Pharma Co., Ltd. $875.0003/15/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 641944257 CMS
Daiichi Sankyo Inc. $30.0003/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695270161 CMS
Daiichi Sankyo Inc. $50.0003/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695270195 CMS
Daiichi Sankyo Inc. $74.9903/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695270935 CMS
Daiichi Sankyo Inc. $30.0003/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695271077 CMS
Daiichi Sankyo Inc. $508.0003/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269695 CMS
Daiichi Sankyo Inc. $50.0003/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695270373 CMS
Daiichi Sankyo Inc. $30.0003/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695270741 CMS
Daiichi Sankyo Inc. $163.5003/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695271301 CMS
Daiichi Sankyo Inc. $74.9903/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695272223 CMS
Daiichi Sankyo Inc. $131.5903/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695274183 CMS
Daiichi Sankyo Inc. $30.0003/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695374775 CMS
Alexion Pharmaceuticals, Inc. $28.5003/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695547041 CMS
Daiichi Sankyo Inc. $163.5003/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269567 CMS
Gilead Sciences, Inc. $3,560.0003/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679312787 CMS
Gilead Sciences, Inc. $26.0003/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552523 CMS
Gilead Sciences, Inc. $65.0003/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552525 CMS
Gilead Sciences, Inc. $3,720.0003/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679312785 CMS
Gilead Sciences, Inc. $182.7703/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679348201 CMS
Gilead Sciences, Inc. $50.0003/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552519 CMS
Gilead Sciences, Inc. $50.0003/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552521 CMS
Daiichi Sankyo Inc. $9,787.5003/07/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269702 CMS
Daiichi Sankyo Inc. $11,475.0003/07/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695274169 CMS
Gilead Sciences, Inc. $105.4903/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552517 CMS
Gilead Sciences, Inc. $300.0003/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679260647 CMS
Gilead Sciences, Inc. $25.0002/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552515 CMS
Daiichi Sankyo Inc. $41.6602/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695268149 CMS
Daiichi Sankyo Inc. $29.2702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695268727 CMS
Daiichi Sankyo Inc. $73.1602/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269279 CMS
Daiichi Sankyo Inc. $29.2702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269341 CMS
Gilead Sciences, Inc. $3,560.0002/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679312779 CMS
Gilead Sciences, Inc. $11.6002/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679348197 CMS
Daiichi Sankyo Inc. $74.9902/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695268701 CMS
Daiichi Sankyo Inc. $50.0002/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695268707 CMS
Daiichi Sankyo Inc. $139.9702/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695268745 CMS
Daiichi Sankyo Inc. $30.0002/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269061 CMS
Daiichi Sankyo Inc. $182.4802/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269179 CMS
Daiichi Sankyo Inc. $30.0002/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269243 CMS
Daiichi Sankyo Inc. $543.0002/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695269385 CMS
Gilead Sciences, Inc. $121.8902/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681552513 CMS
Intercept Pharmaceuticals, Inc. $26.0001/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702089591 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $215,442.85 152
PY2020 $82,686.53 82
PY2021 $87,277.19 66
PY2022 $145,241.93 82
PY2023 $150,634.46 83
PY2024 $174,626.98 93
PY2025 $146,365.35 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $60,841.50 26
PY2025 Principal investigator $8,850.00 2
PY2024 Recipient $75,187.50 17
PY2024 Principal investigator $15,802.50 4
PY2023 Recipient $83,326.52 16
PY2023 Principal investigator $6,312.50 5
PY2022 Recipient $12,745.42 9
PY2022 Principal investigator $675.00 1
PY2021 Recipient $3,125.00 2
PY2021 Principal investigator $5,850.00 5
PY2020 Recipient $4,050.00 2
PY2020 Principal investigator $19,494.00 14
PY2019 Principal investigator $18,271.72 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Boehringer Ingelheim International GmbH $2,500.00 12/22/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779512
Recipient Intercept Pharmaceuticals, Inc. $1,833.28 12/15/2025 Covered Recipient Physician A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248170792
Recipient Intercept Pharmaceuticals, Inc. $166.66 11/15/2025 Covered Recipient Physician A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248170794
Recipient Boehringer Ingelheim International GmbH $2,600.00 10/23/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779510
Recipient Intercept Pharmaceuticals, Inc. $166.66 10/15/2025 Covered Recipient Physician FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH) No dispute reported 06/30/2026 1248170790
Recipient Boehringer Ingelheim International GmbH $3,900.00 09/19/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779508
Recipient Intercept Pharmaceuticals, Inc. $499.98 09/15/2025 Covered Recipient Physician A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248170788
Recipient Boehringer Ingelheim International GmbH $2,600.00 08/18/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779506
Recipient Intercept Pharmaceuticals, Inc. $1,000.00 08/15/2025 Covered Recipient Physician A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248170786
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,375.00 08/07/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223263154
Recipient Boehringer Ingelheim International GmbH $4,600.00 07/28/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779504
Recipient ABBVIE INC. $1,150.00 07/23/2025 Covered Recipient Physician Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity in Adult Participants With Migraine No dispute reported 06/30/2026 1202399649
Recipient ABBVIE INC. $2,550.00 07/14/2025 Covered Recipient Physician A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With An Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects With Episodic Migraine No dispute reported 06/30/2026 1202399645
Recipient Ipsen Bioscience Inc. $1,375.00 07/04/2025 Covered Recipient Physician A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (ELONSEN) No dispute reported 06/30/2026 1176546813
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 06/16/2025 Non-covered Recipient Entity
James H. Lewis, LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220673326
Recipient Boehringer Ingelheim International GmbH $5,400.00 06/16/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779502
Recipient Boehringer Ingelheim International GmbH $4,800.00 06/02/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779500
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,125.00 05/16/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223263152
Recipient Intercept Pharmaceuticals, Inc. $166.66 05/15/2025 Covered Recipient Physician FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH) No dispute reported 06/30/2026 1248170784
Recipient Intercept Pharmaceuticals, Inc. $833.32 04/15/2025 Covered Recipient Physician FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH) No dispute reported 06/30/2026 1248170782
Recipient Intercept Pharmaceuticals, Inc. $166.66 03/12/2025 Covered Recipient Physician FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH) No dispute reported 06/30/2026 1248170780
Recipient Boehringer Ingelheim International GmbH $9,000.00 02/17/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779498
Principal investigator 1 Eli Lilly and Company $7,650.00 01/21/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187872503
Recipient Boehringer Ingelheim International GmbH $400.00 01/20/2025 Covered Recipient Physician A Phase III, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in patients with obesity disease in Japanese No dispute reported 06/30/2026 1220779492
Recipient Boehringer Ingelheim International GmbH $600.00 01/20/2025 Covered Recipient Physician A Phase III, randomized, double-blind, parallel-group, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in Chinese participants with a BMI >=28 kg/m2 or BMI >=24 kg/m2 with at least one weight-related complication No dispute reported 06/30/2026 1220779494
Recipient Boehringer Ingelheim International GmbH $9,600.00 01/15/2025 Covered Recipient Physician A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220779496
Recipient Intercept Pharmaceuticals, Inc. $1,833.28 01/08/2025 Covered Recipient Physician Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC No dispute reported 06/30/2026 1248170778
Recipient Boehringer Ingelheim International GmbH $600.00 01/06/2025 Covered Recipient Physician A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220779490